Suppr超能文献

白血病抑制因子通过Stat3/ID1/MDM2在结直肠癌中对肿瘤抑制因子p53起负调控作用。

LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers.

作者信息

Yu Haiyang, Yue Xuetian, Zhao Yuhan, Li Xiaoyan, Wu Lihua, Zhang Cen, Liu Zhen, Lin Kevin, Xu-Monette Zijun Y, Young Ken H, Liu Juan, Shen Zhiyuan, Feng Zhaohui, Hu Wenwei

机构信息

Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick, New Jersey 08903, USA.

1] Rutgers Cancer Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick, New Jersey 08903, USA [2] Department of Breast Surgery, Qilu Hospital, Shandong University, Ji'nan 250012, China.

出版信息

Nat Commun. 2014 Oct 17;5:5218. doi: 10.1038/ncomms6218.

Abstract

Leukaemia inhibitory factor (LIF) has been recently identified as a p53 target gene, which mediates the role of p53 in maternal implantation under normal physiological conditions. Here we report that LIF is a negative regulator of p53; LIF downregulates p53 protein levels and function in human colorectal cancer (CRC) cells. The downregulation of p53 by LIF is mediated by the activation of Stat3, which transcriptionally induces inhibitor of DNA-binding 1 (ID1). ID1 upregulates MDM2, a key negative regulator of p53, and promotes p53 protein degradation. LIF is overexpressed in a large percentage of CRCs. LIF overexpression promotes cellular resistance towards chemotherapeutic agents in cultured CRC cells and colorectal xenograft tumours in a largely p53-dependent manner. Overexpression of LIF is associated with a poor prognosis in CRC patients. Taken together, LIF is a novel negative regulator of p53, overexpression of LIF is an important mechanism for the attenuation of p53, which promotes chemoresistance in CRCs.

摘要

白血病抑制因子(LIF)最近被鉴定为一种p53靶基因,它在正常生理条件下介导p53在母体着床中的作用。在此我们报告LIF是p53的负调节因子;LIF下调人结肠直肠癌(CRC)细胞中p53的蛋白水平和功能。LIF对p53的下调是由Stat3的激活介导的,Stat3转录诱导DNA结合抑制因子1(ID1)。ID1上调p53的关键负调节因子MDM2,并促进p53蛋白降解。LIF在很大比例的CRC中过表达。LIF过表达在很大程度上以p53依赖的方式促进培养的CRC细胞和结直肠癌异种移植肿瘤对化疗药物的抗性。LIF过表达与CRC患者的不良预后相关。综上所述,LIF是p53的一种新型负调节因子,LIF过表达是p53减弱的重要机制,其促进CRC中的化疗抗性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6ceb/4203416/fde8e3becf31/nihms627794f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验